‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/5688392/height/506/theme/custom/thumbnail/yes/direction/backward/render-playlist/no/custom-color/d4bf69/" height="506" width="100%" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
The Beacon
Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002)
30
00:00:00
/ 00:04:51
30
